Nucleic acid molecules encoding inclusion membrane protein C of
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A69K-039/02
A69K-039/118
A61K-038/04
A61K-038/16
출원번호
US-0756320
(2004-01-14)
발명자
/ 주소
Murdin,Andrew D.
Dunn,Pamela L.
Oomen,Raymond P.
출원인 / 주소
Sanofi Pasteur Limited
인용정보
피인용 횟수 :
0인용 특허 :
12
초록▼
The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an inclusion membrane protein C of
The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an inclusion membrane protein C of a strain of Chlamydia pneumoniae and a promoter to effect expression of the inclusion membrane protein C gene in the host.
대표청구항▼
We claim: 1. A pharmaceutical composition comprising a substantially purified polypeptide capable of inducing an immune response against Chlamydia, said polypeptide being selected from the group consisting of: (a) a polypeptide having the amino acid sequence as set forth in SEO ID NO:3; and (b) a
We claim: 1. A pharmaceutical composition comprising a substantially purified polypeptide capable of inducing an immune response against Chlamydia, said polypeptide being selected from the group consisting of: (a) a polypeptide having the amino acid sequence as set forth in SEO ID NO:3; and (b) a fragment of the polypeptide in (a), said fragment comprising at least 12 amino acids and being capable of inducing an immune response against Chlamydia; wherein said substantially purified polypeptide is the only Chlamydia-derived polypeptide in said composition. 2. A method for inducing an immune response against Chlamydia, comprising administering to a subject an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide capable of inducing an immune response against Chlamydia, said polypeptide being selected from the group consisting of: (a) a polypeptide having the amino acid sequence as set forth in SEO ID NO:3; and (b) a fragment of the polypeptide in (a), said fragment comprising at least 12 amino acids and being capable of inducing an immune response against Chlamydia; wherein said substantially purified polypeptide is the only Chlamydia-derived polypeptide in said composition. 3. The pharmaceutical composition according to claim 1, wherein, in (b), said fragment comprises at least 20 amino acids. 4. The pharmaceutical composition according to claim 1, wherein, in (b), said fragment comprises at least 50 amino acids. 5. The pharmaceutical composition according to claim 1, wherein, in (b), said fragment comprises at least 100 amino acids. 6. The pharmaceutical composition according to claim 1, wherein said polypeptide comprises SEQ ID NO: 3. 7. The method according to claim 2, wherein, in (b), said fragment comprises at least 20 amino acids. 8. The method according to claim 2, wherein, in (b), said fragment comprises at least 50 amino acids. 9. The method according to claim 2, wherein, in (b), said fragment comprises at least 100 amino acids. 10. The method according to claim 2, wherein said polypeptide comprises SEQ ID NO: 3. 11. A fusion polypeptide comprising a first polypeptide fused to a second polypeptide wherein said first polypeptide is a substantially purified polypeptide capable of inducing an immune response against Chlamydia said first polypeptide being selected from the group consisting of: (a) a polypeptide having the amino acid sequence as set forth in SEO ID NO:3; and (b) a fragment of the polypeptide in (a), said fragment comprising at least 12 amino acids and being capable of inducing an immune response against Chlamydia. 12. The fusion polypeptide according to claim 11, wherein said second polypeptide comprises a His tag. 13. The fusion polypeptide according to claim 11, wherein said second polypeptide has adjuvant activity. 14. The pharmaceutical composition according to claim 1, comprising a pharmaceutically acceptable adjuvant. 15. The pharmaceutical composition according to claim 1, wherein, in (b), said fragment comprises at least 75 amino acids. 16. The method according to claim 2, wherein, in (b), said fragment comprises at least 75 amino acids.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (12)
Lai Jiunu (Los Angeles CA) Lee Jar-How (Los Angeles CA) Lin Yun-Long (Los Angeles CA) Ray Dan (Encino CA) Wilcox Gary (Malibu CA), AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques.
Nantz Michael H. (Department of Chemistry ; Univ. or California Davis CA 95616) Bennett Michael J. (4849 El Cemonte Ave. ; #163 Davis CA 95616) Malone Robert W. (1016 Bienville St. Davis CA 95616), Cationic transport reagents.
Studier F. William (Stony Brook NY) Davanloo Parichehre (Basel NY CHX) Rosenberg Alan H. (Setauket NY) Moffatt Barbara A. (East Lansing MI) Dunn John J. (Bellport NY), Cloning and expression of the gene for bacteriophage T7 RNA polymerase.
Epand Richard M. (Hamilton CAX) Bottega Remo (Ancaster,both of PA CAX) Huang Leaf (Upper St. Claim PA), Method for delivering nucleic acids into cells.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Method for transporting substances into living cells and tissues and apparatus therefor.
Christou Paul (Madison WI) McCabe Dennis (Middleton WI) Swain William F. (Madison WI) Barton Kenneth A. (Middleton WI), Particle-mediated transformation of soybean plants and lines.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.